Ginsenoside Rg1 promotes the efficacy of human amnion-derived mesenchymal stem cells in alleviating chemotherapy-induced premature ovarian insufficiency in rats.

ABSTRACT:

Background

Premature ovarian insufficiency (POI) can cause multiple sequelae in young women and is currently incurable. Mesenchymal stem cell (MSC)-based treatment of POI shows great promise. However, some limitations affect their efficacy in POI treatment, and exploration of methods to improve their efficacy is necessary. This study aimed to explore whether Rg1 can improve the efficacy of human amnion-derived MSC (hAD-MSC) transplantation in the treatment of rats with chemotherapy-induced POI.

Methods

hAD-MSCs were isolated from human amnions. One hundred female SD rats were divided into control, POI, Rg1, hAD-MSCs and Rg1 + hAD-MSCs groups. POI rat models were first established by intraperitoneal injection of cisplatin, and then the rats in the hAD-MSCs and Rg1 + hAD-MSCs

SUBMITTER: Zeng J 

PROVIDER: S-EPMC12649030 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature